Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1998, p. 2765-2767, Vol. 42, No. 10
The Clinical Microbiology Institute,
Wilsonville, Oregon 97070
Received 23 February 1998/Returned for modification 26 May
1998/Accepted 3 July 1998
Because of its capacity to neutralize the lethality of
gram-negative bacterial endotoxic lipopolysaccharides, PMX-622
(polymyxin B bound to dextran 70) is being developed for possible
adjunctive therapy of gram-negative sepsis. In this study, it was
determined that the in vitro antimicrobial activity of PMX-622 was
minimal and that it does not interfere with the in vitro antimicrobial activity of 11 antibiotics commonly used to treat gram-negative infections.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
PMX-622 (Polymyxin B-Dextran 70) Does Not Alter In
Vitro Activities of 11 Antimicrobial Agents
*
Corresponding author. Mailing address: 9725 SW
Commerce Circle, Suite A1, Wilsonville, OR 97070. Phone: (503)
682-3232. Fax: (503) 682-2065. E-mail: cmi{at}hevanet.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»